Compound: suxibuzone
SMILES: O=C1N(N(c2ccccc2)C(C1(COC(=O)CCC(=O)O)CCCC)=O)c3ccccc3
InChIKey: ONWXNHPOAGOMTG-UHFFFAOYSA-N
Synonyms: suxibuzone, 27470-51-5, Suxibuzona, Suxibuzonum, 4-((4-Butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy)-4-oxobutanoic acid, 4-Hydroxymethylbutazolidine hemisuccinate, 4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid, DTXSID6021296, 86TDZ5WP2B, 4-Butyl-4-hydroxymethyl-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinate, NSC-757866, CHEBI:32173, DTXCID601296, RefChem:890070, 1,2-Diphenyl-4-n-butyl-4-hydroxymethyl-3,5-dioxopyrazolidine Hemisuccinate, 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione, M02AA22, 248-477-6, Calibene, Flogos, Solurol, AE-17, 4-Butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinate (ester), 4-BUTYL-4-[HYDROXYMETHYL]-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE HYDROGEN SUCCINATE [ESTER], Succinic acid, monoester with 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione, NCGC00016799-01, Aflogan, Flamilon, Alfide, CAS-27470-51-5, 3,5-Pyrazolidinedione, 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-, hydrogen succinate (ester), Suxibuzonum [INN-Latin], Suxibuzona [INN-Spanish], Butanedioic acid, mono((4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl) ester, Butanedioic acid, mono[(4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl] ester, AE 17, SR-01000841241, EINECS 248-477-6, UNII-86TDZ5WP2B, BRN 0904563, Suxibuzon, Suxibuzone [INN:BAN:JAN], Suxibuzone CRS, Suxibuzone; 4-[(4-Butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid, Prestwick_113, MFCD00079562, Suxibuzone (Standard), Spectrum_000321, Suxibuzone (JAN/INN), SUXIBUZONE [INN], SUXIBUZONE [JAN], Prestwick0_000658, Prestwick1_000658, Prestwick2_000658, Prestwick3_000658, Spectrum2_000966, Spectrum3_000664, Spectrum4_000433, Spectrum5_001113, Epitope ID:124941, 4-Butyl-4-(beta-carboxypropionyl-oxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione, SUXIBUZONE [MART.], 3-((4-Butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methoxycarbonyl)propionsaeure, SUXIBUZONE [WHO-DD], SCHEMBL25810, BSPBio_000695, BSPBio_002327, KBioGR_000786, KBioSS_000801, MLS002153938, DivK1c_000171, SPECTRUM1501157, SPBio_000971, SPBio_002616, BPBio1_000765, orb1710722, CHEMBL1414320, SUXIBUZONE [EP IMPURITY], HMS500I13, HY-B1079R, KBio1_000171, KBio2_000801, KBio2_003369, KBio2_005937, KBio3_001547, BRD5826, SUXIBUZONE [EP MONOGRAPH], NINDS_000171, HMS1570C17, HMS1923I17, HMS2097C17, HMS2232E17, HMS3371A12, HMS3714C17, HMS5083M15, Pharmakon1600-01501157, BRD-5826, HY-B1079, Tox21_110615, Tox21_202352, Tox21_302778, CCG-40180, NSC757866, AKOS024374988, Tox21_110615_1, CS-4635, DB13232, NSC 757866, 4-{[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl]oxy}-4-oxobutanoic acid, IDI1_000171, NCGC00016799-02, NCGC00016799-03, NCGC00016799-04, NCGC00016799-05, NCGC00016799-06, NCGC00016799-08, NCGC00095261-01, NCGC00095261-02, NCGC00095261-03, NCGC00095261-04, NCGC00256470-01, NCGC00259901-01, MS-27855, SMR001233279, SBI-0051667.P002, DB-047228, AB00052229, NS00008152, ST51015119, D01289, F85232, AB00052229_08, AB00052229_09, Q7650623, SR-01000841241-2, SR-01000841241-3, BRD-K78815826-001-05-4, BRD-K78815826-001-08-8, BRD-K78815826-001-13-8, BRD-K78815826-001-14-6, Suxibuzone, European Pharmacopoeia (EP) Reference Standard, 4-[(4-Butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methoxy]-4-oxobutanoic acid, 4-[(4-butyl-3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)methoxy]-4-oxo-butanoic acid, 4-Butyl-4-(.beta.-carboxypropionyl-oxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione, 3-{[(4-butyl-3,5-dioxo-1,2-diphenyl-1,2-diazolidin-4-yl)methyl]oxycarbonyl}pro panoic acid
Theoretical properties:
molecular_formula: C24H26N2O6
molecular_weight: 438.5 g/mol
exact_mass: 438.17908655 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 11
heavy_atom_count: 32
topological_polar_surface_area: 104 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Suxibuzone is a pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antirheumatic drug, a peripheral nervous system drug and a prodrug. It is a hemisuccinate, a monocarboxylic acid and a member of pyrazolidines.
chebi: A pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses.
chembl: SUXIBUZONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Suxibuzone is an analgesic used for joint and muscular pain.  It is a prodrug of the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone, and is commonly used in horses.